C4 Therapeutics, Inc. (CCCC) community
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value
$2.76−0.01 (-0.36%)
Close on Nov 13, 2026Market cap $339.55MP/E –Yield –
Community
Notes and questions about C4 Therapeutics from other investors
No posts about CCCC yet
Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.
See a number that looks wrong?